Medicamen Biotech Limited, a prominent player in the biotech sector, has announced its financial results for the second quarter and half-year ended September 30, 2025, showcasing robust performance and improved liquidity position.

Financial Highlights

The company's Board of Directors approved the unaudited standalone and consolidated financial results, revealing noteworthy figures:

Significant Cash Position Improvement

One of the most striking aspects of Medicamen Biotech's financial report is the substantial increase in its cash and bank balances. The company's liquid assets grew from Rs. 358.03 lakhs in the previous year to Rs. 4,351.23 lakhs, marking a remarkable growth of approximately 1,115%.

Capital Raising Success

The dramatic improvement in Medicamen Biotech's cash position can be attributed to successful capital raising activities. The company reported:

This capital infusion has significantly bolstered the company's financial standing, providing a strong foundation for future growth and operational expansion.

Regulatory Compliance

In compliance with the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements Regulations, 2015, Medicamen Biotech's Board of Directors convened on November 14, 2025, to approve these financial results. The meeting began at 2:30 PM and concluded at 3:45 PM.

The company has also submitted Limited Review Reports from Rai Qimat & Associates, Chartered Accountants, for both standalone and consolidated financial results, ensuring transparency and adherence to regulatory standards.

Investors and stakeholders can access the detailed unaudited financial results for the quarter and half-year ended September 30, 2025, on the company's official website at www.medicamen.com .

This strong financial performance, particularly the enhanced cash position, positions Medicamen Biotech favorably for potential future initiatives in the dynamic biotech sector.

Medicamen Biotech , a prominent player in the biotech sector, has announced significant developments following its recent board meeting held on August 12, 2025. The company has approved its unaudited financial results for the quarter ended June 30, 2025, and made key changes to its board composition.

Board Appointments and Changes

In a strategic move to strengthen its leadership, Medicamen Biotech has appointed three new directors:

1. Mr. Ashwani Kumar Sharma has been elevated from his role as Non-Executive Director to Executive Director. His appointment as Whole-time Director is for a period of five years, effective August 12, 2025. Mr. Sharma brings valuable experience in managing supply chain activities from his tenure at Shivalik Rasayan Limited.

2. Mr. Sham Goel joins as a Non-Executive Independent Director. A Chartered Accountant with over 30 years of experience in finance, taxation, and accounts, Mr. Goel's expertise includes financial analysis and taxation matters. He is currently a Director at Essem Logistics Limited.

3. Mr. Shaival Saurabh has been appointed as a Non-Executive Independent Director. With more than 30 years of experience in branding and advertising, Mr. Saurabh has a proven track record in helping both small and large corporates achieve brand growth through effective marketing strategies.

These appointments are subject to shareholder approval and are set for a term of five years each, commencing from August 12, 2025.

Financial Results and Dividend Proposal

The board has approved the unaudited financial results for Q1 FY26 (quarter ended June 30, 2025). While specific financial figures were not disclosed in the announcement, the company noted that the auditors have provided unmodified opinions on the quarterly results, indicating a clean audit report.

In a move that may please shareholders, the board has proposed a final dividend of 10% or Re. 1.00 per equity share for the financial year 2024-25. This proposal will be subject to approval at the upcoming Annual General Meeting (AGM).

Upcoming Annual General Meeting

Medicamen Biotech has scheduled its 32nd AGM for September 26, 2025, at 12:00 noon. In line with modern practices, the meeting will be held through Video Conference (VC) or Other Audio-Visual Means (OAVM).

Key dates related to the AGM include:

The book closure is to facilitate the payment of the final dividend, if approved by shareholders at the AGM.

Conclusion

These developments at Medicamen Biotech, including the board restructuring and the proposed dividend, reflect the company's commitment to strong corporate governance and shareholder value. The addition of experienced professionals to the board is expected to bring fresh perspectives and expertise to guide the company's future growth strategies.

Investors and stakeholders will likely look forward to more detailed financial information and future outlook during the upcoming AGM.